Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1
Author(s) -
A. Lehnhardt,
Claartje Karnatz,
Thurid Ahlenstiel-Grunow,
Kerstin Benz,
Marcus R. Benz,
Klemens Budde,
Anja Büscher,
Thomas Fehr,
Markus Feldkötter,
Norbert Graf,
Britta Höcker,
Therese Jungraithmayr,
Günter Klaus,
B Koehler,
Martin Konrad,
Birgitta Kranz,
Carmen Montoya,
Dominik N. Müller,
Thomas J. Neuhaus,
Jun Oh,
Lars Pape,
Martin Pöhl,
Brigitte RoyerPokora,
Uwe Querfeld,
Reinhard Schneppenheim,
Hagen Staude,
Giuseppina Spartà,
Kirsten Timmermann,
Frauke Wilkening,
Simone Wygoda,
Carsten Bergmann,
Markus J. Kemper
Publication year - 2015
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.10141014
Subject(s) - medicine , wilms' tumor , suppressor , gene , mutation , heterozygote advantage , cancer research , tumor suppressor gene , genetics , pathology , oncology , cancer , allele , carcinogenesis , biology
The Wilms tumor suppressor gene 1 (WT1) plays an essential role in urogenital and kidney development. Genotype/phenotype correlations of WT1 mutations with renal function and proteinuria have been observed in world-wide cohorts with nephrotic syndrome or Wilms tumor (WT). This study analyzed mid-European patients with known constitutional heterozygous mutations in WT1, including patients without proteinuria or WT.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom